| 2024-12-13 |
Trastuzumab: Transforming the Landscape of Breast Cancer Treatment |
| 2024-11-18 |
Rituximab: The First Monoclonal Antibody Approved for Cancer Treatment |
| 2024-11-11 |
How Antibodies are Used in Cancer Immunotherapy |
| 2024-10-08 |
Mechanisms of Action of Bispecific Antibodies in Cancer Therapy |
| 2024-10-08 |
Week 2, October 2024: ADCs in Regulatory Review |
| 2024-10-06 |
Antibody-Drug Conjugates and Immune Checkpoint Inhibitors in Cancer Treatment |
| 2024-10-04 |
September 2024: Bispecific Antibodies in Oncology |
| 2024-09-24 |
Week 4, September 2024: Anti-TIGIT Therapies |
| 2024-09-10 |
Week 2, September 2024: Non-Small Cell Lung Cancer |
| 2024-08-09 |
Transforming In Vivo Research with Bispecific Antibodies |
| 2024-07-30 |
Week 5, July 2024: ADCs & Gynecologic Cancer |
| 2024-07-26 |
Antibody-Mediated Phagocytosis Against Cancer |
| 2024-06-28 |
Immune Checkpoint Inhibitors and Antibody Therapeutics: A Paradigm Shift in Cancer Treatment |
| 2024-06-25 |
Week 4, June 2024: Immune Checkpoint Blockade |
| 2024-06-14 |
Multi-Payload Antibody–Drug Conjugates |
